Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling
Effects of osteoporosis drugs on proximal femur cortical and trabecular bone were studied using dual-energy x-ray absorptiometry (DXA)-based 3D modeling method. Changes observed in this head-to-head study were consistent with those obtained using computed tomography in the literature.
The aim of the present study was to assess the effects of osteoporosis drugs on cortical and trabecular bone at the proximal femur using DXA-based 3D modeling.
We retrospectively analyzed 155 patients stratified by treatments: naive of treatment (NAIVE), alendronate (AL), denosumab (DMAB), and teriparatide (TPTD). DXA scans were performed at baseline and after treatment, and areal bone mineral density at spine and femur were measured. A software algorithm (3D-SHAPER) was used to derive 3D models from hip DXA scans and compute: trabecular and cortical volumetric BMD (vBMD), cortical thickness (Cth), and cortical surface BMD (cortical sBMD). Changes from baseline were normalized at 24 months and evaluated in terms or percentage.
After 24 months, a non-significant decrease was observed for trabecular vBMD, Cortical sBMD, Cth, and cortical vBMD (− 2.3, − 0.8, − 0.3, and − 0.5%) in the NAIVE group. Under AL and DMAB, significant increases were observed in trabecular vBMD (3.8 and 7.3%), cortical vBMD (1.4 and 2.0%), and cortical sBMD (1.5 and 3.6%). An increase in Cth was observed in patients under DMAB (1.8%). Under TPTD, a significant increase in Trabecular vBMD was observed (5.9%) associated with a non-significant increase of Cth (+ 1%) concomitant with a decrease in cortical vBMD (− 1.1%).
Results obtained in this head-to-head study are consistent with those obtained using computed tomography in the literature. DXA-based modeling techniques could complement standard DXA examination to monitor treatment effects on trabecular and cortical compartments.
Keywords3D modeling Cortical and trabecular bones DXA Femur Osteoporosis treatments
Areal bone mineral density at lumbar spine in grams per square centimeter
Areal bone mineral density at femoral neck in grams per square centimeter
Areal bone mineral density at total femur in grams per square centimeter
- Trabecular vBMD
Trabecular volumetric bone mineral density in milligrams per cubic centimeter
- Cortical vBMD
Cortical volumetric bone mineral density in milligrams per cubic centimeter
- Cortical sBMD
Cortical surface bone mineral density in milligrams per square centimeter
Cortical thickness in millimeters
The work of Renaud Winzenrieth is supported by: Programa Estatal de Promoción del Talento y su Empleabilidad - Torres Quevedo, Ministerio de Economía y Competitividad (Reference: PTQ-16-08627).
Compliance with ethical standards
Conflicts of interest
R. Winzenrieth is an employee of Galgo Medical. L. Humbert is a stockholder of Galgo Medical. S. Di Gregorio; E. Bonel, M. García, and L. Del Rio have no conflict of interest.
- 3.Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541CrossRefPubMedGoogle Scholar
- 11.Genant HK, Libanati C, Engelke K, Zanchetta JR, Høiseth A, Yuen CK, Stonkus S, Bolognese MA, Franek E, Fuerst T, Radcliffe HS, McClung MR (2013) Improvements in hip trabecular , subcortical , and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. Bone 56:482–488. https://doi.org/10.1016/j.bone.2013.07.011 CrossRefPubMedGoogle Scholar
- 12.Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM (2008) Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res 23:1974–1982. https://doi.org/10.1359/JBMR.080805 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Engelke K, Lang T, Khosla S, Qin L, Zysset P, Leslie WD, Shepherd JA, Schousboe JT (2015) 2015 ISCD position development conference clinical use of quantitative computed tomography (QCT) of the hip in the management of osteoporosis in adults: the 2015 ISCD official positions d part I. J Clin Densitom 18:338–358. https://doi.org/10.1016/j.jocd.2015.06.012 CrossRefPubMedGoogle Scholar
- 14.Johannesdottir F, Aspelund T, Reeve J, Poole KE, Sigurdsson S, Harris TB, Gudnason VG, Sigurdsson G (2013) Similarities and differences between sexes in regional loss of cortical and trabecular bone in the mid-femoral neck: the AGES - Reykjavik longitudinal study. J Bone Miner Res 28:2165–2176. https://doi.org/10.1002/jbmr.1960 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Black DM, Bouxsein ML, Marshall LM, Cummings SR, Lang TF, Cauley JA, Ensrud KE, Nielson CM, Orwoll ES, Osteoporotic Fractures in Men (MrOS) Research Group (2008) Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res 23:1326–1333. https://doi.org/10.1359/JBMR.080316 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22:149–157. https://doi.org/10.1359/JBMR.061011 CrossRefPubMedGoogle Scholar
- 19.Genant HK, Engelke K, Hanley DA, Brown JP, Omizo M, Bone HG, Kivitz AJ, Fuerst T, Wang H, Austin M, Libanati C (2010) Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 47:131–139. https://doi.org/10.1016/j.bone.2010.04.594 CrossRefPubMedGoogle Scholar
- 21.Zysset P, Pahr D, Engelke K, Genant HK, McClung MR, Kendler DL, Recknor C, Kinzl M, Schwiedrzik J, Museyko O, Wang A, Libanati C (2015) Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology. Bone 81:122–130. https://doi.org/10.1016/j.bone.2015.06.025 CrossRefPubMedGoogle Scholar
- 25.Borggrefe J, Graeff C, Nickelsen TN, Marin F, Glüer CC (2010) Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 25:472–481. https://doi.org/10.1359/jbmr.090820 CrossRefPubMedGoogle Scholar
- 26.Zysset P, Qin L, Lang T, Khosla S, Leslie WD, Shepherd JA, Schousboe JT, Engelke K (2015) 2015 ISCD position development conference clinical use of quantitative computed tomography e based finite element analysis of the hip and spine in the management of osteoporosis in adults: the 2015 ISCD official positions d part II. J Clin Densitom 18:359–392. https://doi.org/10.1016/j.jocd.2015.06.011 CrossRefPubMedGoogle Scholar
- 29.Clotet J, Martelli Y, Di Gregorio S, et al (2017) Structural parameters of the proximal femur by 3-dimensional dual-energy x-ray absorptiometry software: comparison with quantitative computed tomography. J Clin Densitom 1–13. https://doi.org/10.1016/j.jocd.2017.05.002
- 34.Brown JP, Prince R, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153–161. https://doi.org/10.1359/JBMR.0809010 CrossRefPubMedGoogle Scholar
- 35.Bolognese MA, Teglbjærg CS, Zanchetta JR, Lippuner K, McClung MR, Brandi ML, Høiseth A, Lakatos P, Moffett AH, Lorenc RS, Wang A, Libanati C (2013) Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom 16:147–153. https://doi.org/10.1016/j.jocd.2012.02.006 CrossRefPubMedGoogle Scholar
- 36.Sánchez A, Brun LR, Salerni H, Costanzo PR, González D, Bagur A, Oliveri B, Zanchetta MB, Farías V, Maffei L, Premrou V, Mansur JL, Larroudé MS, Sarli MA, Rey P, Ulla MR, Pavlove MM, Karlsbrum S, Brance ML (2016) Effect of denosumab on bone mineral density and markers of bone turnover among postmenopausal women with osteoporosis. J Osteoporos 2016:1–6. https://doi.org/10.1155/2016/8738959 CrossRefGoogle Scholar
- 37.Senn C, Günther B, Popp AW, Perrelet R (2014) Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int 25:1945–1951. https://doi.org/10.1007/s00198-014-2703-8 CrossRefPubMedGoogle Scholar
- 38.Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical. Bone 47:493–502. https://doi.org/10.1016/j.bone.2010.05.022 CrossRefPubMedGoogle Scholar
- 41.Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, Thomas T, Boutroy S, Bogado CE, Bilezikian JP, Seeman E (2014) Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone 59:173–179. https://doi.org/10.1016/j.bone.2013.11.016 CrossRefPubMedGoogle Scholar
- 44.Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25:1886–1894. https://doi.org/10.1002/jbmr.81 CrossRefPubMedPubMedCentralGoogle Scholar
- 45.Ma YL, Zeng QQ, Chiang AY, Burr D, Li J, Dobnig H, Fahrleitner-Pammer A, Michalská D, Marin F, Pavo I, Stepan JJ (2014) Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone 59:139–147. https://doi.org/10.1016/j.bone.2013.11.011 CrossRefPubMedGoogle Scholar